Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.

K I Pritchard1, P E Goss, L Shepherd

  • 1Division of Clinical Trials and Epidemiology, Toronto-Sunnybrook Regional Cancer Center, 2075 Bayview Avenue, North York, Ont., Canada M4N 3M5. kathy.pritchard@sw.ca

Breast (Edinburgh, Scotland)
|February 28, 2006
PubMed
Summary

Letrozole, an aromatase inhibitor, significantly reduced breast cancer recurrence by 42% compared to placebo after 5 years of tamoxifen. This extended adjuvant therapy offers a survival benefit, particularly for node-positive patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing outbreak simulation training: a collaborative pilot study for dual-specialty medical trainees and infection prevention and control professionals.

The Journal of hospital infection·2024
Same author

A tiered approach to inpatient psychosocial screening in an adult UK burns service.

Burns : journal of the International Society for Burn Injuries·2021
Same author

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience.

Breast cancer research and treatment·2020
Same author

Nodal disease predicts recurrence whereas other traditional factors affect survival in a cohort of South African patients with differentiated thyroid carcinoma.

Cancers of the head & neck·2019
Same author

Postoperative care advice: who cares?

British dental journal·2019
Same author

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2019

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Letrozole is the only approved aromatase inhibitor for extended adjuvant therapy post-tamoxifen.
  • The NCIC CTG MA.17 trial established letrozole's efficacy in reducing breast cancer recurrence.

Purpose of the Study:

  • To evaluate the efficacy and safety of letrozole in the extended adjuvant treatment of breast cancer.
  • To assess the impact of letrozole on disease-free survival and overall survival.

Main Methods:

  • The study involved postmenopausal women who completed 5 years of tamoxifen therapy.
  • A randomized, placebo-controlled trial design was utilized (NCIC CTG MA.17).
  • Updated analyses were performed at 30 months with a median follow-up exceeding 2 years.

Main Results:

Related Experiment Videos

  • Letrozole decreased breast cancer recurrence risk by 42% compared to placebo.
  • A 4.8% improvement in 4-year disease-free survival was observed.
  • Benefits included improved distant disease-free recurrence and survival, especially in node-positive patients.

Conclusions:

  • Letrozole is effective as extended adjuvant therapy, significantly reducing recurrence and improving survival in postmenopausal breast cancer patients.
  • Concomitant zoledronic acid may manage bone loss associated with letrozole therapy.